PN 23114
Alternative Names: PN-23114Latest Information Update: 01 Feb 2024
At a glance
- Originator Protagonist Therapeutics
- Class Peptides
- Mechanism of Action Iron modulators; Metal-transporting-protein-1-inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemochromatosis; Sickle cell anaemia
Most Recent Events
- 09 Dec 2023 Preclinical trials in Sickle cell anaemia in USA (SC)
- 09 Dec 2023 Pharmacodynamics data from a preclinical study presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 16 Jan 2023 Pharmacodynamics data from a preclinical trial in Hemochromatosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)